Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.
2.

Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).

Matchar DB, Thakur ME, Grossman I, McCrory DC, Orlando LA, Steffens DC, Goldstein DB, Cline KE, Gray RN.

Evid Rep Technol Assess (Full Rep). 2007 Jan;(146):1-77. Review.

3.

Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors.

Thakur M, Grossman I, McCrory DC, Orlando LA, Steffens DC, Cline KE, Gray RN, Farmer J, DeJesus G, O'Brien C, Samsa G, Goldstein DB, Matchar DB.

Genet Med. 2007 Dec;9(12):826-35. Review.

PMID:
18091432
4.

Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2014 Apr;16(4):338-46. doi: 10.1038/gim.2013.141. Epub 2013 Sep 26. Review.

PMID:
24071797
5.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
6.

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2009 Jan;11(1):15-20. doi: 10.1097/GIM.0b013e31818efd9d.

7.

Recommendations from the EGAPP Working Group: does genomic profiling to assess type 2 diabetes risk improve health outcomes?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group; Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Aug;15(8):612-7. doi: 10.1038/gim.2013.9. Epub 2013 Mar 14.

PMID:
23492873
8.

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.

Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO; EGAPP Working Group.

Genet Med. 2009 Jan;11(1):3-14. doi: 10.1097/GIM.0b013e318184137c.

9.

Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*.

Genet Med. 2016 Aug;18(8):770-9. doi: 10.1038/gim.2015.173. Epub 2015 Dec 17.

PMID:
26681310
10.

Recommendations from the EGAPP Working Group: genomic profiling to assess cardiovascular risk to improve cardiovascular health.

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2010 Dec;12(12):839-43. doi: 10.1097/GIM.0b013e3181f872c0.

PMID:
21042222
11.

Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2011 Jan;13(1):67-76. doi: 10.1097/GIM.0b013e3181fbe46f.

PMID:
21150787
12.

Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.

Edwards SJ, Hamilton V, Nherera L, Trevor N.

Health Technol Assess. 2013 Nov;17(54):1-190. doi: 10.3310/hta17540. Review.

13.

Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2009 Jan;11(1):35-41. doi: 10.1097/GIM.0b013e31818fa2ff.

14.

Neither cytochrome P450 family genes nor neuroendocrine factors could independently predict the SSRIs treatment in the Chinese Han population.

Zhang X, Yu T, Li X, Li X, Huang X, Li X, He L, He G, Sun X.

Pharmacopsychiatry. 2014 Mar;47(2):60-6. doi: 10.1055/s-0033-1361095. Epub 2014 Jan 31.

PMID:
24488700
15.

Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2009 Jan;11(1):66-73. doi: 10.1097/GIM.0b013e3181928f56.

16.

Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis.

Eke AC, Saccone G, Berghella V.

BJOG. 2016 Nov;123(12):1900-1907. doi: 10.1111/1471-0528.14144. Epub 2016 May 30. Review.

17.

Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.

Probst-Schendzielorz K, Viviani R, Stingl JC.

Expert Opin Drug Metab Toxicol. 2015;11(8):1219-32. doi: 10.1517/17425255.2015.1052791. Epub 2015 Jun 1. Review.

PMID:
26028357
18.

Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management.

Nelson LS, Erdman AR, Booze LL, Cobaugh DJ, Chyka PA, Woolf AD, Scharman EJ, Wax PM, Manoguerra AS, Christianson G, Caravati EM, Troutman WG.

Clin Toxicol (Phila). 2007 May;45(4):315-32. Review.

PMID:
17486478
19.

The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.

Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, Jorgensen A, Payne K, Pirmohamed M, Pushpakom S, Walley T, de Warren-Penny P, Dickson R.

Health Technol Assess. 2010 Jan;14(3):1-157, iii. doi: 10.3310/hta14030. Review.

20.

The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients.

Smits KM, Smits LJ, Peeters FP, Schouten JS, Janssen RG, Smeets HJ, van Os J, Prins MH.

Psychiatr Genet. 2008 Aug;18(4):184-90. doi: 10.1097/YPG.0b013e3283050aca.

PMID:
18628680

Supplemental Content

Support Center